The present invention relates to caps for medical connectors, and more particularly to caps that can be used to protect the sterility of unconnected medical connectors, such as connectors that may be used for fluid flow or for fluid delivery systems.
Bloodstream infections, such as may be caused by microorganisms that enter patients via intravascular catheters, are a significant cause of illness and excess medical costs. A substantial number of such infections occur in U.S. intensive care units annually. Additionally, a significant fraction of these infections result in death.
Guidelines from the Centers for Disease Control and Prevention describe various ways to limit bloodstream infections in hospital, outpatient, and home care settings. The guidelines address issues such as hand hygiene, catheter site care, and admixture preparation. However, despite these guidelines, such infections continue to plague healthcare systems at relatively unchanged rates.
Impregnating catheters with various antimicrobial agents is one approach for reducing these infections. Impregnated catheters, however, provide less than satisfactory results. Additionally, some microbes have developed resistance to the various antimicrobial agents used in the catheters. Other systems and approaches have also been developed, but these likewise suffer from a variety of limitations and drawbacks.
In accordance with one embodiment of the invention, there is provided a female-disinfecting cap for threadingly accepting a needleless injection site and applying an antiseptic agent to the needleless injection site. In this embodiment, the cap includes a cap body having an inner sidewall defining a chamber having an opening for accepting the needleless injection site. The sidewall has a piloting zone devoid of threads and immediately adjacent to the opening. The piloting zone has a first diameter. The sidewall also has an initial threading zone immediately adjacent to the piloting zone. The initial threading zone has a first diameter. The sidewall also has a transition zone immediately adjacent the initial threading zone. The transition zone has a transitioning diameter. The sidewall also has a main zone immediately adjacent the transition zone. The main zone has a second diameter. The second diameter is less than first diameter. The transitioning diameter changes from the first diameter, at the point where the transition zone contacts the initial threading zone, to the second diameter at the point where the transitioning zone contacts the main zone. In some embodiments, the cap also includes an absorbent material for holding the antiseptic agent disposed in the chamber. The cap also includes a pair of threads that protrude from the sidewall and extend from the initial threading zone, through the transition zone and into the main zone, but do not extend into the piloting zone.
Preferably, in some embodiments the first diameter is between 0.31 inches and 0.32 inches inclusive.
In a preferred embodiment, the first diameter is between 0.314 inches and 0.316 inches inclusive. In a further preferred embodiment, the first diameter is 0.315 inches.
In a preferred embodiment, the pilot zone extends from the opening to a depth of between 0.02 inches to 0.03 inches inclusive.
In another preferred embodiment, the pilot zone extends from the opening to a depth of between 0.024 inches to 0.026 inches inclusive. Preferably, the pilot zone extends from the opening to a depth of 0.025 inches.
In another preferred embodiment, the first diameter extends from the opening to a depth of 0.057 inches to 0.067 inches inclusive. Preferably, the first diameter extends from the opening to a depth of between 0.061 inches to 0.063 inches inclusive. Preferably, the first diameter extends from the opening to a depth of 0.062 inches.
In another preferred embodiment, the initial threading zone extends from the end of the pilot zone to a depth of 0.057 inches to 0.067 inches inclusive from the opening. Preferably, the initial threading zone extends from the end of the pilot zone to a depth of 0.062 inches from the opening. Preferably, the transition zone begins at a depth of 0.057 inches to 0.067 inches from the opening inclusive and extends to a depth of 0.075 inches to 0.125 inches inclusive. Also preferably, the transition zone begins at a depth of 0.062 inches from the opening and extends to a depth of 0.100 inches from the opening.
In a preferred embodiment, the second diameter is between 0.298 inches and 0.302 inches inclusive. Preferably, the second diameter is 0.3 inches.
In other embodiments, the threading, has a radial height sufficient to define an inner threading diameter of between 0.287 inches and 0.291 inches inclusive. Optionally, the threading has a radial height sufficient to define an inner threading diameter of not less than 0.287 inches.
In related embodiments, the threading has a width, in the longitudinal direction of the cap, of between 0.020 inches and 0.025 inches inclusive.
In other embodiments, the cap further includes the antiseptic agent.
In other embodiments, the cap further includes a gripping portion.
Also, in other embodiments, the cap further includes a cover disposed over the opening of the chamber. Optionally, the cover includes an impervious pliable material.
In one embodiment, a method is provided for applying a female-disinfecting cap and applying an antiseptic agent to a needleless injection site. The method includes placing a cap having a pilot zone over the needleless injection site. The pilot zone turns freely on the needleless injection site without interference form the diameter of the pilot zone. The method also includes engaging the threads of the needleless injection site in a thread starting zone. The thread starting zone also turns freely on the needleless injection site without interference at the diameter of the zone, and further without interference from the threads of the cap. The thread starting zone has the same diameter as the pilot zone. The method further includes turning the cap once the threads have engaged the threads of the needleless injection site so as to draw the needleless injection site into a transition zone in which the diameter progressively reduces from the diameter of the pilot and thread starting zones and the diametric fit of the needleless injection site at the outer diameter of the transition zone begins to interfere with the outer diameter of the threads of the needleless injection site, so as to create an interference acting to retain the cap to the needleless injection site and to resist unintended rotation and removal of the cap during use. Optionally, the cap is turned further on the needleless injection site further drawing the needleless injection site into a main zone of the cap in which the outer diameter of the main zone further interferes with the outer diameter of the threads of the needleless injection site.
The foregoing features of embodiments will be more readily understood by reference to the following detailed description, taken with reference to the accompanying drawings, in which:
In
In
In
Disclosed herein are caps that can be used to protect and/or disinfect medical connectors. Systems and methods related to such caps are also disclosed. A medical connector cap is a cap for a medical connector, such as (but not limited to) a luer connector. A “female medical connector cap” is a cap for a female medical connector. A “male medical connector cap” is a cap for a male medical connector. The cap may, but need not necessarily, include a disinfectant. The cap may, but need not necessarily, be capable of cleaning or disinfecting the medical connector for which it is a cap.
An example of medical connectors for which caps disclosed herein may be used are intravascular connectors associated with a fluid pathway, such as an IV line. Commonly, a fluid pathway is used to intermittently administer medications to a patient. For example, a fluid pathway, which communicates fluids with a patient's blood stream, may have one or more connectors associated therewith. Each of the fluid pathway connectors can be connected to other connectors, such as a connector associated with a central line. In such a situation, the medical connectors, such as luer lock connectors, are connected and disconnected at various times, and may remain disconnected for several minutes or hours. Medical connector caps are used to cover and protect the various medical connectors while the connectors are separated from one another. When the medical connectors are separated from each other, there are two connectors that each can benefit from being covered by a cap. Therefore, in some cases, it can be advantageous to have a single connector set that can be used to provide protection for both ends of a separated connection. In other or further embodiments, a cap can include an antiseptic for disinfecting a medical connector. In some cases, it can be advantageous for the cap to form a seal with the medical connector to thereby prevent the antiseptic from exiting the cap into the fluid pathway.
In some embodiments, the medical connector comprises a needleless injection site, which may sometimes be referred to as a needleless injection port, hub, valve, or device, or as a needleless access site, port, hub, valve, or device, and which can include such brands as, for example, Clave® (available from ICU Medical, Inc.), SmartSite® (available from Cardinal Health, Inc.), and Q-Syte™ (available from Becton, Dickinson and Company). Stated otherwise, in some embodiments, the cap can be suitably connected with any of a variety of different needless injection sites, such as those previously listed. In certain embodiments, once cap has been applied to or coupled with connector, it is unnecessary to disinfect (e.g. treat with an alcohol swab) the connector prior to each reconnection of the connector with another connector, as the connector will be kept in an uncontaminated state while coupled with the cap. Use of the cap thus can replace the standard swabbing protocol.
Needleless Injection Sites (NIS) are intended to be compliant with the ISO luer thread standard (ISO 594-2), but vary dimensionally, even within the standard. The ISO standard does not anticipate mating caps that lack a luer post—such as disinfecting caps. The problem is providing a secure fit which will not become loose with time and use. In a standard luer connection, the securement is provided by the locking taper fit of the male luer post in the female luer. In a disinfecting cap for an NIS, there is no luer post, and the securement must be provided by other features. In the design presented herein, and the securement may be provided by slight interference between an inner diameter of the cap, and an outer diameter of the NIS. For example, major thread diameter of the cap and the major thread diameter of the NIS may provide the interference fit, as discussed in more detail below.
The challenge is providing a fit which has sufficient interference to provide security in use, but not so much interference as to be difficult to install. This is complicated by the dimensional variation in the range of NIS brands and models on the market. There are many different brands of NISs in the marketplace, and disinfecting caps should attach to each of the various available models securely. Otherwise, a disinfecting cap may be able to be secured on some NISs but not others.
Two NISs that pose particular problems for securely attaching disinfecting caps are the Q-Syte NIS 100 and some versions of the SmartSite NIS 200. These two models, the Q-Syte NIS 100 and the SmartSite NIS 200, show the wide dimensional variation among NISs. Some embodiments of the present invention provide a secure fit which does not allow the cap to fall off the NIS during normal use and wear. Some embodiments prevent damage to a septum 108 of the Becton Dickinson Q-Syte NIS 100. Some embodiments provide the previously mentioned functions on a range of NIS brands and models.
Two other examples of NISs 300 and 400 are shown in
The cap 501 has a new bore and thread design with the following features: a Piloting Counter bore (Zone 1) 510 having a Counter Bore first diameter 507 at the opening 512 of the cap 501 to provide centering of the cap 501 over the mating NIS prior to and during starting engagement of the threads 514 of the cap 501. (This Zone 1 510 may be referred to as a piloting zone 510.)
Following the pilot counter bore (Zone 1) 510 there is a free running zone (Zone 2) 520 in which the cap threads 514 are allowed to begin threading engagement of the threads of a medical connector without resistance. (This Zone 2 520 may be referred to as an initial threading zone 520.)
The thread width 516 (in all zones 510, 520, 530 and 540) is sized in the longitudinal direction 518 to easily engage a range of mating NIS models without interference in the longitudinal direction 518.
A minor diameter 503 of the thread 514 (in all zones 510, 520, 530 and 540) is sized to prevent pinching—and associated damage—of the Q-syte silicone septum 108. See
A second diameter 505 of the main bore (Zone 4) 540, also referred to as the cap major thread diameter 505, is sized diametrically to provide thread 514 locking interference with a range of NISs. This second diameter 505 is carefully specified to maintain an ease of engagement as well. (This Zone 4 540 may be referred to as a main zone 540.) In some embodiments, side walls 526 of the main bore 540 may have a taper. In a preferred embodiment, each wall of the main bore 540 may have a taper of approximately 1 degree relative to the longitudinal axis 518. However, in other embodiments, the walls 526 of the main bore 540 may not be tapered.
Between the Piloting Counter bore 510 and Main Bore 540, a ramp or taper Transition (Zone 3) 530 is provided. In the taper zone 530 the diameter of the side wall 526 tapers between the bore first diameter 507 and the second diameter 505. The angle of the transition is chosen to balance the need for a rapid transition in bore with the need for the increase in resistance to installation occurring at the transition to be gentle. (This Zone 3 530 may be referred to as a transition zone 530.) In some embodiments, and in particular with some NISs, the inner diameter of the transition zone 530 may provide the interference fit with the medical connector. For example, in some embodiments, the threads of the medical connector may have an interference fit with the inner diameter of the cap in the transition zone 530.
A set of preferred dimensions for embodiments of the invention which work with a range of NIS dimensions are shown in Table 2:
The pad 1032 can be formed of a deformable, resilient material. The pad 1032 can be compressed within the cap 501a when the cap 501a is coupled to a medical connector, such as a needleless injection site. More specifically, during the connection of the cap 501a to a medical connector, the cap 501a and the pad 1032 rotate relative to an opening edge of the medical connector, thereby drawing the medical connector into the cap 501a. The rotation of the cap 501a causes the pad 1032 to wipe or scrub the opening edge of the medical connector. Pad 1032 and any antiseptic 1033 disposed within cap 501a can thus cleanse and disinfect the opening edges of the medical connector. The pad 1032 can also be formed such that when a medical connector is coupled to the cap 501a, the pad 1032 is deformed such that the pad 1032 extends around the opening edges and/or threads of the medical connector. For example, the pad 1032 can be formed such that as the cap 501a is twisted onto the medical connector, the pad 1032 deforms around the threads and/or the opening edges of the medical connector, thereby scrubbing the threads and/or the opening edge of the medical connector. Further, the pad 1032 can expand to its original shape when the medical connector is removed from the cap 501a.
The pad 1032 can also provide additional functionality when a liquid antiseptic 1033 is disposed within the cap 501a. In particular, the pad 1032 acts as a sponge to absorb or release the liquid antiseptic within the cap 501a. More specifically, when the pad 1032 is compressed by the medical connector, pad 1032 releases at least a portion of the antiseptic 1033 so that the antiseptic 1033 can be transferred to the opening edges of the medical connector. Conversely, when a medical connector is disconnected from the cap 501a, the pad 1032 expands and absorbs excess antiseptic 1033 so that the antiseptic 1033 does not drip or spill out of the cap 501a.
In some embodiments, the pad 1032 can be deformable, and can also be configured to retain an antiseptic 1033. In some further embodiments, the pad 1032 can be resiliently deformable. For example, the pad 1032 can comprise any suitable sponge-like material, such as an elastomeric foam, any open-cell foam, felt, or non-woven fiber matrix, and can be configured to conform to the contours of a portion of a medical connector that is introduced into the disinfection chamber 1022. The pad 1032 can also comprise any closed-cell foam, as well as a solid elastomeric foam such as silicone or the like.
The pad 1032 can have a series or network of openings or spaces therein that can retain the antiseptic 1033 when the pad 1032 is in an expanded state. For example, the antiseptic 1033 can be received within, occupy, fill (or partially fill), wet, soak, or saturate at least a fraction of the pad 1032, or stated otherwise, can fill the pad 1032 to a given concentration level. Compression of the pad 1032 can cause antiseptic 1033 to egress from the pad 1032 so as to contact the medical connector. Resilient expansion of the foam upon removal of a compressive force can allow the pad 1032 to soak up or absorb at least some of the antiseptic 1033 that had previously been forced from the pad 1032. In some embodiments, the antiseptic 1033 can comprise any liquid antiseptic, such as alcohol (e.g., isopropyl alcohol) at various concentrations ranging from 50-90%, ethanol at various concentrations ranging from 50-95%, and combinations of any alcohols with any antiseptics, or a dry material, such as chlorhexidine, ethylenediaminetetraacetic acid (EDTA), lodaphors, or any suitable combination thereof. Accordingly, although the antiseptic 1033 is schematically depicted in as a series of droplets, the antiseptic 1033 is not necessarily liquid and may fill the pad 1032 to a greater or lesser extent than what is shown. In the illustrated embodiment, when the disinfection chamber 1022 is in a sealed state (e.g., in its pre-use condition), the pad 1032 may be in a relaxed, expanded, or uncompressed state in a longitudinal direction. It is noted that the pad 1032 may be uncompressed in one or more dimensions, yet compressed in one or more other dimensions, when in the pre-use state. For example, the pad 1032 can be expanded or in a relaxed state in a longitudinal direction, yet compressed radially inwardly via the sidewall 1012, when the cap 501a is in the pre-use state. The pad 1032 may be uncompressed in the longitudinal direction when the cap 501a does is not interacting with the connection interface of the medical connector.
In the illustrated embodiment, the pad 1032 is substantially cylindrical and defines an outer diameter that may be approximately the same size as an inner diameter of the threads 514a. In other embodiments, the outer diameter of the pad 1032 can be larger than the inner diameter of the threads 514a so as to be radially compressed and held tighter within the disinfection chamber 1022. In further embodiments, the pad 1032 can include threading that projects radially inwardly and that is complementary to the threads 514a to thereby secure the pad 1032 within the chamber 1022.
When the cap 501a is coupled with the medical connector, the coupling action can bring a portion of the medical connector into contact with the pad 1032 and can allow the pad 1032 to wipe or scrub the medical connector, as described above. Likewise, the antiseptic 1033 can be forced into contact with the medical connector during the coupling phase and can remain in contact with the medical connector, while the cap 501a is coupled with the medical connector. The connection interface can cooperate with a connection interface of the medical connector to maintain the cap 501a in an attached configuration relative to the connector. Moreover, the connection interface can couple with the medical connector, such as via complementary threading, so as to prevent antiseptic from leaking from the disinfection chamber 1022.
In some embodiments, such as where the pad 1032 is formed of a material that is not fully elastically resilient or that requires a relatively long relaxation time in which to transition from a compressed state to a relaxed or uncompressed state (e.g., in a longitudinal direction), pre-use storage in the relaxed or uncompressed state in at least one dimension can preserve or enhance the cleaning, scrubbing, or disinfection properties of the pad 1032. For example, as the pad 1032 is coupled with the medical connector (e.g., the NIS 400 of
Various parameters can be adjusted to determine the amount of antiseptic 1033 that is expelled from the pad 1032 when the pad 1032 is coupled with a medical connector. For example, the depth to which the medical connector is received within the disinfection chamber 1022, the concentration of antiseptic 1033 within the pad 1032, and/or other parameters can be altered. In various embodiments, no less than about ¼, no less than about ⅓, no less than about ½, no less than about ⅔, or no less than about ¾ of the antiseptic 1033 is expelled from the pad 1032 when the pad 1032 is coupled with a medical connector. In some embodiments, all, or substantially all, of the antiseptic 1033 is expelled from the pad 1032.
The carrier 21 includes at least one mounting hole 23, located to facilitate mounting of the carrier at one end, and may optionally include a pair of mounting holes 23 at each end or any desired number of mounting holes 23. One of the mounting holes 23 may be used, for example, to hang the carrier 21 on a hook or other member protruding from an IV pole. Alternatively, a pair of mounting holes 23 may be used simultaneously to mount the carrier 21 in an approximately horizontal orientation. The carrier 21 also includes an array of holes 22 for receiving therein a corresponding population of medical connector caps, in a manner discussed in further detail below.
In the embodiment of
In
In
As described in connection with
Although we have just shown how as part of the single gesture the sealing tab 32 may be removed from the connector cap, the sealing tab (and the tether 323 and tip 321) may be configured so that when a user prepares the selected one of the caps for use, a user can choose to manipulate the cap in relation to the carrier (for example, by twisting it in place) so as to break the tether, and thereafter remove the cap from its corresponding hole, while leaving the cover portion of the sealing tab to sealingly cover the openable end of the cap. In this manner, a user may remove the cover portion at a desired time after removing the cap from its corresponding hole.
The embodiments of the invention described above are intended to be merely exemplary; numerous variations and modifications will be apparent to those skilled in the art. All such variations and modifications are intended to be within the scope of the present invention as defined in any appended claims.
While specific parameter values may be recited for disclosed embodiments, within the scope of the invention, the values of all of parameters may vary over wide ranges to suit different applications.
While the invention is described through the above-described exemplary embodiments, modifications to, and variations of, the illustrated embodiments may be made without departing from the inventive concepts disclosed herein. Furthermore, disclosed aspects, or portions thereof, may be combined in ways not listed above and/or not explicitly claimed. Accordingly, the invention should not be viewed as being limited to the disclosed embodiments.
This application claims priority from provisional U.S. patent application No. 62/024,162, filed Jul. 14, 2014, entitled, “Disinfecting Cap for Needleless Injection Sites,” and naming Donald D. Solomon and F. Mark Ferguson as inventors, the disclosure of which is incorporated herein, in its entirety, by reference.
Number | Name | Date | Kind |
---|---|---|---|
1744026 | Paltzley | Oct 1926 | A |
1868200 | Freedman | Jul 1932 | A |
2356969 | Blum | May 1942 | A |
2299037 | Saueressig | Oct 1942 | A |
2351804 | Blum | Jun 1944 | A |
3315830 | Flynn | Apr 1967 | A |
3431548 | Busler | Mar 1969 | A |
3446596 | Salivar et al. | May 1969 | A |
3976311 | Spendlove | Aug 1976 | A |
3987930 | Fuson | Oct 1976 | A |
4121727 | Robbins et al. | Oct 1978 | A |
4232677 | Leibinsohn | Nov 1980 | A |
4299330 | Walter | Nov 1981 | A |
4324239 | Gordon et al. | Apr 1982 | A |
4334551 | Pfister | Jun 1982 | A |
4344551 | Pfister | Jun 1982 | A |
4340052 | Dennehey et al. | Jul 1982 | A |
4346703 | Dennehey et al. | Aug 1982 | A |
4354490 | Rogers | Oct 1982 | A |
4369781 | Gilson et al. | Jan 1983 | A |
4402691 | Rosenthal et al. | Sep 1983 | A |
4432764 | Lopez | Feb 1984 | A |
4432766 | Pellotti et al. | Feb 1984 | A |
4440207 | Genatempo et al. | Apr 1984 | A |
4450624 | Collier | May 1984 | A |
4572373 | Johansson | Feb 1986 | A |
4597758 | Aalto et al. | Jul 1986 | A |
4624664 | Peluso et al. | Nov 1986 | A |
4667837 | Vitello et al. | May 1987 | A |
4671306 | Spector | Jun 1987 | A |
4778447 | Velde et al. | Oct 1988 | A |
4798303 | Arnold | Jan 1989 | A |
4810241 | Rogers | Mar 1989 | A |
4838875 | Somor | Jun 1989 | A |
D303631 | Demarest | Sep 1989 | S |
D310542 | Regnault | Sep 1990 | S |
4991629 | Ernesto et al. | Feb 1991 | A |
5006114 | Rogers et al. | Apr 1991 | A |
5165559 | Kusz | Nov 1992 | A |
5184742 | Decaprio et al. | Feb 1993 | A |
D333788 | Peschwender | Mar 1993 | S |
5190534 | Cendell | Mar 1993 | A |
5195957 | Tollini | Mar 1993 | A |
5205821 | Kruger et al. | Apr 1993 | A |
5242425 | White et al. | Sep 1993 | A |
D340112 | Zeman | Oct 1993 | S |
D341227 | Lang et al. | Nov 1993 | S |
5269771 | Thomas et al. | Dec 1993 | A |
5385372 | Utterberg | Jan 1995 | A |
5439451 | Collinson et al. | Aug 1995 | A |
5445270 | Pratz | Aug 1995 | A |
5451113 | Lund et al. | Sep 1995 | A |
5466219 | Lynn et al. | Nov 1995 | A |
5492147 | Challender et al. | Feb 1996 | A |
5536258 | Folden | Jul 1996 | A |
5554135 | Menyhay | Sep 1996 | A |
5593055 | Repp | Jan 1997 | A |
5620427 | Werschmidt et al. | Apr 1997 | A |
5624057 | Lifshey | Apr 1997 | A |
5694978 | Heilmann et al. | Dec 1997 | A |
5702017 | Goncalves | Dec 1997 | A |
5738663 | Lopez | Apr 1998 | A |
5792120 | Menyhay | Aug 1998 | A |
5839715 | Leinsing | Nov 1998 | A |
5894015 | Rechtin | Apr 1999 | A |
5951519 | Utterberg | Sep 1999 | A |
5954657 | Rados | Sep 1999 | A |
5954957 | Chin-Loy et al. | Sep 1999 | A |
6045539 | Menyhay | Apr 2000 | A |
6152913 | Feith et al. | Nov 2000 | A |
6171287 | Lynn et al. | Jan 2001 | B1 |
D456668 | Tse | May 2002 | S |
D468015 | Horppu | Dec 2002 | S |
D470888 | Kuboshima | Feb 2003 | S |
6523686 | Bae | Feb 2003 | B1 |
6695160 | Culley | Feb 2004 | B1 |
6932795 | Lopez et al. | Aug 2005 | B2 |
6960191 | Howlett et al. | Nov 2005 | B2 |
7014169 | Newton et al. | Mar 2006 | B2 |
7040598 | Raybuck | May 2006 | B2 |
7040669 | Kenmotsu et al. | May 2006 | B2 |
7198611 | Donnell et al. | Apr 2007 | B2 |
D545964 | Blanco | Jul 2007 | S |
D547446 | Racz et al. | Jul 2007 | S |
D550355 | Racz et al. | Sep 2007 | S |
7282186 | Lake, Jr. et al. | Oct 2007 | B2 |
7316669 | Ranalletta | Jan 2008 | B2 |
D573643 | Brigham et al. | Jul 2008 | S |
D607325 | Rogers et al. | Jan 2010 | S |
7762524 | Cawthon et al. | Jul 2010 | B2 |
7762988 | Vitello | Jul 2010 | B1 |
7763006 | Tennican | Jul 2010 | B2 |
7780794 | Rogers et al. | Aug 2010 | B2 |
D632574 | Huntington et al. | Feb 2011 | S |
7922701 | Buchman | Apr 2011 | B2 |
D639421 | Sano et al. | Jun 2011 | S |
7985302 | Rogers et al. | Jul 2011 | B2 |
8167847 | Anderson et al. | May 2012 | B2 |
8172825 | Solomon et al. | May 2012 | B2 |
8177761 | Howlett | May 2012 | B2 |
8197749 | Howlett | Jun 2012 | B2 |
8231587 | Solomon et al. | Jul 2012 | B2 |
8231602 | Anderson et al. | Jul 2012 | B2 |
8273303 | Ferlic et al. | Sep 2012 | B2 |
8328767 | Solomon et al. | Dec 2012 | B2 |
8343112 | Solomon et al. | Jan 2013 | B2 |
8419713 | Solomon et al. | Apr 2013 | B1 |
8523830 | Solomon et al. | Sep 2013 | B2 |
8523831 | Solomon et al. | Sep 2013 | B2 |
8641681 | Solomon et al. | Feb 2014 | B2 |
8647308 | Solomon et al. | Feb 2014 | B2 |
8647326 | Solomon et al. | Feb 2014 | B2 |
8740864 | Hoang | Jun 2014 | B2 |
8784388 | Charles et al. | Jul 2014 | B2 |
8808637 | Ferlic | Aug 2014 | B2 |
8961475 | Solomon et al. | Feb 2015 | B2 |
9079692 | Solomon et al. | Jul 2015 | B2 |
9101750 | Solomon et al. | Aug 2015 | B2 |
9114915 | Solomon et al. | Aug 2015 | B2 |
9242084 | Solomon et al. | Jan 2016 | B2 |
9283369 | Ma et al. | Mar 2016 | B2 |
9352140 | Kerr et al. | May 2016 | B2 |
20020093192 | Matkovich | Jul 2002 | A1 |
20030140441 | Stafford | Jul 2003 | A1 |
20030153865 | Connell et al. | Aug 2003 | A1 |
20030181849 | Castellanos | Sep 2003 | A1 |
20030198502 | Maloney et al. | Oct 2003 | A1 |
20040039341 | Ranalletta | Feb 2004 | A1 |
20040195136 | Young et al. | Oct 2004 | A1 |
20040201216 | Segal et al. | Oct 2004 | A1 |
20040214316 | O'Connell | Oct 2004 | A1 |
20040258560 | Lake, Jr. et al. | Dec 2004 | A1 |
20050033267 | Decaria | Feb 2005 | A1 |
20050038397 | Newton et al. | Feb 2005 | A1 |
20050124970 | Kunin et al. | Jun 2005 | A1 |
20050147524 | Bousquet | Jul 2005 | A1 |
20050183971 | Petricca | Aug 2005 | A1 |
20050203460 | Kim | Sep 2005 | A1 |
20050245883 | Baldwin | Nov 2005 | A1 |
20050265773 | De Laforcade | Dec 2005 | A1 |
20050266714 | Higgins et al. | Dec 2005 | A1 |
20060030827 | Raulerson et al. | Feb 2006 | A1 |
20060177250 | Nakagaki | Aug 2006 | A1 |
20070112333 | Hoang et al. | May 2007 | A1 |
20070202177 | Hoang | Aug 2007 | A1 |
20070282280 | Tennican | Dec 2007 | A1 |
20070287989 | Crawford et al. | Dec 2007 | A1 |
20070293818 | Stout et al. | Dec 2007 | A1 |
20070293822 | Crawford et al. | Dec 2007 | A1 |
20080019889 | Rogers et al. | Jan 2008 | A1 |
20080021381 | Lurvey et al. | Jan 2008 | A1 |
20080027399 | Harding et al. | Jan 2008 | A1 |
20080033371 | Updegraff et al. | Feb 2008 | A1 |
20080038167 | Lynn | Feb 2008 | A1 |
20080039803 | Lynn | Feb 2008 | A1 |
20080097407 | Plishka | Feb 2008 | A1 |
20080086091 | Anderson et al. | Apr 2008 | A1 |
20080095680 | Steffens et al. | Apr 2008 | A1 |
20080105704 | Pritchard | May 2008 | A1 |
20080107564 | Sternberg et al. | May 2008 | A1 |
20080132880 | Buchman | Jun 2008 | A1 |
20080147047 | Davis et al. | Jun 2008 | A1 |
20080177250 | Howlett et al. | Jul 2008 | A1 |
20080190485 | Guala | Aug 2008 | A1 |
20080235888 | Vaillancourt et al. | Oct 2008 | A1 |
20090008393 | Howlett et al. | Jan 2009 | A1 |
20090062766 | Howlett et al. | Mar 2009 | A1 |
20090099529 | Anderson et al. | Apr 2009 | A1 |
20090149819 | Chelak | Jun 2009 | A1 |
20090205151 | Fisher et al. | Aug 2009 | A1 |
20090287160 | Sudo | Nov 2009 | A1 |
20100003067 | Shaw et al. | Jan 2010 | A1 |
20100047123 | Solomon et al. | Feb 2010 | A1 |
20100049170 | Solomon | Feb 2010 | A1 |
20100063482 | Mansour et al. | Mar 2010 | A1 |
20100100056 | Cawthon et al. | Apr 2010 | A1 |
20100242993 | Hoang et al. | Sep 2010 | A1 |
20100306938 | Rogers et al. | Dec 2010 | A1 |
20100313366 | Rogers et al. | Dec 2010 | A1 |
20110044850 | Solomon et al. | Feb 2011 | A1 |
20110054440 | Lewis | Mar 2011 | A1 |
20110064512 | Shaw et al. | Mar 2011 | A1 |
20110064515 | Ruckey et al. | Mar 2011 | A1 |
20110165020 | Truggvason | Jul 2011 | A1 |
20110213341 | Solomon et al. | Sep 2011 | A1 |
20110217212 | Solomon et al. | Sep 2011 | A1 |
20110232020 | Rogers et al. | Sep 2011 | A1 |
20110265825 | Rogers | Nov 2011 | A1 |
20110277788 | Rogers et al. | Nov 2011 | A1 |
20110290754 | Taber | Dec 2011 | A1 |
20110314619 | Schweikert | Dec 2011 | A1 |
20120016318 | Hoang et al. | Jan 2012 | A1 |
20120039764 | Solomon | Feb 2012 | A1 |
20120039765 | Solomon | Feb 2012 | A1 |
20120082977 | Rajagopal et al. | Apr 2012 | A1 |
20120216359 | Rogers et al. | Aug 2012 | A1 |
20130019421 | Rogers et al. | Jan 2013 | A1 |
20130072908 | Solomon et al. | Mar 2013 | A1 |
20130171030 | Ferlic et al. | Jul 2013 | A1 |
20130197485 | Gardner et al. | Aug 2013 | A1 |
20130299445 | Cerracchio | Nov 2013 | A1 |
20140001182 | Wood | Jan 2014 | A1 |
20140010481 | Last | Jan 2014 | A1 |
20140135739 | Solomon et al. | May 2014 | A1 |
20140227144 | Dickson | Aug 2014 | A1 |
20140360968 | Barth | Dec 2014 | A1 |
20150217106 | Banik et al. | Aug 2015 | A1 |
20150231384 | Ma et al. | Aug 2015 | A1 |
20150273199 | Adams et al. | Oct 2015 | A1 |
20150374968 | Solomon et al. | Dec 2015 | A1 |
20160038701 | White et al. | Feb 2016 | A1 |
20160045629 | Gardner et al. | Feb 2016 | A1 |
20160106968 | Solomon et al. | Apr 2016 | A1 |
20170245618 | Chen et al. | Aug 2017 | A1 |
20190099593 | Avula et al. | Apr 2019 | A1 |
20190209781 | Solomon et al. | Jul 2019 | A1 |
20210016077 | Avula et al. | Jan 2021 | A1 |
Number | Date | Country |
---|---|---|
205549223 | Sep 2016 | CN |
0229789 | Jul 1987 | EP |
0462355 | Dec 1991 | EP |
64002760 | Jan 1989 | JP |
2004035245 | Apr 2004 | WO |
2006099306 | Sep 2006 | WO |
2007097985 | Aug 2007 | WO |
2008089196 | Jul 2008 | WO |
2008100950 | Aug 2008 | WO |
2010002808 | Jan 2010 | WO |
2010141508 | Dec 2010 | WO |
2011141508 | Dec 2010 | WO |
2011053924 | May 2011 | WO |
2011066565 | Jun 2011 | WO |
2011066586 | Jun 2011 | WO |
2013184716 | Dec 2013 | WO |
2015174953 | Nov 2015 | WO |
Entry |
---|
European Search Report dated Mar. 6, 2012 for EP08727689.5. |
European Search Report dated Jun. 20, 2017 for EP10827614.8. |
Office Action dated Apr. 22, 2011 for U.S. Appl. No. 12/164,310. |
Office Action dated Dec. 23, 2010 for U.S. Appl. No. 12/014,388. |
International Search Report and Written Opinion dated Aug. 1, 2008 for PCT/US2008/051087. |
International Search Report and Written Opinion dated Aug. 31, 2009 for PCT/US2009/049094. |
Notice of Allowance dated Jun. 7, 2017 for U.S. Appl. No. 14/162,207. |
International Search Report and Written Opinion dated Jan. 6, 2011 for PCT/US2010/054995. |
International Search Report and Written Opinion dated Feb. 7, 2011 for PCT/US2010/058453. |
Office Action dated Jan. 27, 2010 for U.S. Appl. No. 12/014,388. |
Office Action dated Jun. 9, 2011 for U.S. Appl. No. 12/171,997. |
Office Action dated Aug. 16, 2010 for U.S. Appl. No. 12/164,310. |
Office Action dated May 5, 2009 for U.S. Appl. No. 12/014,388. |
Office Action dated Jun. 21, 2010 in U.S. Appl. No. 12/014,388. |
International Search Report and Written Opinion dated Jan. 26, 2011 for PCT/US2010/058404. |
Baxa Corporation Launches PadLock Set Saver for IV Safety press release, 2 pages, available at http://www.pr.com/press-release/55432. ,Oct. 10, 2007. |
Baxa Corporation Padlock catalog, 3 pages, copyright 2009, available at http://www.baxa.com/SearchResults/ProductDetail/?id-6452BFB9-3048-7B87-701697FB93902BA6. |
Baxa Corporation Padlock Microbial Testing Technical Paper, copyright 2007, 4 pages, available at http://www.baxa.com/resources/docs/technicalPapers/PadLockMicrobialChallengeTechPaper.pdf. |
Baxa Corporation PadLock Set Saver Specifications and Instructions for Use, copyright 2007, 2 pages, available at http://www.baxa.com/resources/docs/5300103905C.pdf. |
BD Q-Syte Luer Access Split Septum product brochure, 4 pages, available at http://www.bd.com/infusion/pdfs/D16333.pdf. ,Nov. 2008. |
Braun product catalog, 2pages. ,Aug. 2008. |
Curos Port Protector, web page from http://www.iveramed.com/ ,Jul. 11, 2008. |
Curos Port Protector product brochure, 2 pages, available at http://www.iveramed.com/clocs/Curos%20Brochure--FINAL.pdf. ,Nov. 2008. |
Hospira Male/Female Sterile Cap product packaging insert and brochure, 2 pages. ,Aug. 2004. |
Kippmed Vented Non-Vented Female Luer Lock Caps, The KippGroup, ,Jan. 1995 ,2 pgs. |
Stoker, et al., One Less Problem, Safe Practices when Administering IV Therapy, Managing Infection Control, 4 pgs ,Jun. 2008. |
Tego Connector product brochure, 2 pages, available at http://www.icumed.com/Docs-Tego/M1-1148%20TEG0%20Folder%20Brochure%20Rev.3.pdf. ,Nov. 2008. |
Unomedical Medical Products catalog, 2 pages, available at http://www.unomedical.net/au/section05/section10/LocalSSI/..%5C..%5Cpdf%5Cmedical.pdf ,Jan. 2006. |
Buchman, et al., A New Central Venous Catheter Cap: Decreased Microbial Growth and Risk for Catheter-Related Bloodstream Infection, The Journal of Vascular Access ,2009 ,11-21. |
Maki, et al., In Vitro Studies of a Novel Antimicrobial Luer-Activated Needleless Connector for Prevention of Catheter-belated Blookstream Infection, Clinical Infection Diseases, vol. 50, Issue 12 ,Jun. 15, 2010 ,1580-1587. |
Menyhay, et al., Disinfection of Needleless Catheter Connecors and Access Ports with Alcohol May Not Prevent Microbial Entry: The Promise of a Novel Antiseptic-Barrier Cap, Infection control and Hospital Epidemiology, vol. 27 No. 1 ,Jan. 2006 ,23-27. |
Notice of Allowance dated Sep. 1, 2017 for U.S. Appl. No. 14/162,207. |
Office Action dated Feb. 27, 2018 for U.S. Appl. No. 14/978,925. |
Office Action dated Apr. 4, 2018 for U.S. Appl. No. 14/845,004. |
Office Action dated May 25, 2018 for U.S. Appl. No. 15/203,002. |
Office Action dated Oct. 20, 2017 for U.S. Appl. No. 15/203,002. |
Office Action dated Nov. 17, 2017 for U.S. Appl. No. 14/845,004. |
International Search Report and Written Opinion dated Jan. 24, 2019 for PCT/US2018/054202. |
International Search Report and Written Opinion dated Feb. 1, 2017 for PCT/US2016/062061. |
International Search Report and Written Opinion dated Jun. 22, 2018 for PCT/US2018/014237. |
Notice of Allowance dated Sep. 17, 2018 for U.S. Appl. No. 14/845,004. |
Notice of Allowance dated Oct. 25, 2018 for U.S. Appl. No. 14/947,341. |
Notice of Allowance dated Nov. 9, 2018 for U.S. Appl. No. 15/203,002. |
Office Action dated Jun. 7, 2018 for U.S. Appl. No. 14/947,341. |
Office Action dated Sep. 14, 2018 for U.S. Appl. No. 14/978,925. |
European Search Report dated Jun. 13, 2019 for EP16866954.7. |
Office Action dated Jun. 3, 2019 for U.S. Appl. No. 14/978,925. |
Office Action dated Aug. 30, 2019 for U.S. Appl. No. 15/797,213. |
European Search Report dated Mar. 25, 2020 for EP15808498.8. |
Notice of Allowance dated Dec. 19, 2019 for U.S. Appl. No. 15/979,213. |
European Search Report dated Jun. 9, 2020 for EP18744486.4. |
Office Action dated Jun. 25, 2020 for U.S. Appl. No. 16/235,584. |
Office Action dated Oct. 14, 2020 for U.S. Appl. No. 16/150,966. |
European Search Report dated Jun. 28, 2021 for EP18865254.9. |
Office Action dated Jun. 18, 2021 for U.S. Appl. No. 16/235,584. |
Notice of Allowance dated Apr. 6, 2021 for U.S. Appl. No. 16/150,966. |
Office Action dated Mar. 8, 2021 for U.S. Appl. No. 16/235,584. |
Office Action dated Jan. 5, 2023 for U.S. Appl. No. 16/836,678. |
Number | Date | Country | |
---|---|---|---|
62024162 | Jul 2014 | US |